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Microvascular endothelial cells maintain a tight bar-
rier to prevent passage of plasma and circulating
immune cells into the extravascular tissue compart-
ment, yet endothelial cells respond rapidly to vasoac-
tive substances, including thrombin, allowing tran-
sient paracellular permeability. This response is a
cornerstone of acute inflammation, but the mecha-
nisms responsible are still incompletely understood.
Here, we demonstrate that thrombin triggers MALT1
to proteolytically cleave cylindromatosis (CYLD).
Fragmentation of CYLD results in microtubule disrup-
tion and a cascade of events leading to endothelial
cell retraction and an acute permeability response.
This finding reveals an unexpected role for the
MALT1 protease, which previously has been viewed
mostly as a driver of pro-inflammatory NF-kB sig-
naling in lymphocytes. Thus, MALT1 not only pro-
motes immune cell activation but also acutely regu-
lates endothelial cell biology, actions that together
facilitate tissue inflammation. Pharmacologic inhibi-
tion of MALT1 may therefore have synergistic impact
by targeting multiple disparate steps in the overall in-
flammatory response.INTRODUCTION
The CARMA1-Bcl10-MALT1 (CBM) signaling complex mediates
nuclear factor kB (NF-kB) activation in B and T lymphocytes in
response to antigen presentation (Thome, 2004). As such, theCell R
This is an open access article under the CC BY-Ncomplex plays a critical role in the adaptive immune system; de-
ficiencies in any of the three components, in both humans and
mice, lead to impaired lymphocyte activation in the face of anti-
genic challenge and to susceptibility to infection (Pe´rez de Diego
et al., 2015; Thome, 2004; Turvey et al., 2014). MALT1 is viewed
as the effector protein of the CBM complex and operates
through two distinct mechanisms (Afonina et al., 2015). First,
MALT1 acts as a scaffold and recruits additional proteins,
including the kinase TAK1 and the ubiquitin ligase TRAF6, which
directly activate the IkB kinase (IKK) complex. IKK activation, in
turn, induces the canonical NF-kB pathway. Second, MALT1
possesses a caspase-like protease activity, which targets nine
known cellular substrates for site-specific cleavage (Afonina
et al., 2015; Juilland and Thome, 2016; McAllister-Lucas and Lu-
cas, 2008). Several of these, including RelB, CYLD, and A20, are
negative regulators of canonical NF-kB signaling, operating
downstream of the IKK complex (Brummelkamp et al., 2003;
D€uwel et al., 2009; Hailfinger et al., 2011; Stilo et al., 2008;
Sun, 2010), so that MALT1-dependent cleavage and destruction
of these important regulators has the potential to undermine
their capacity to inhibit NF-kB at distal points in the signaling
pathway (Afonina et al., 2015). In this way, MALT1 proteolytic
activity serves as a rheostat to optimize and sustain the overall
NF-kB signal that is directly induced through MALT1 scaffolding
activity.
Over the last 15 years, our understanding of the CBM com-
plex and the functions of MALT1 has advanced primarily through
the study of B and T cells. However, we and others have shown
that a CARMA1 homolog, CARMA3 (CARD10/Bimp1), exists in
a broad array of non-immune cells and directs NF-kB activa-
tion through an analogous CARMA3-containing CBM complex
(Grabiner et al., 2007; McAllister-Lucas et al., 2001, 2007;
Wang et al., 2001). In vascular endothelial cells, this CBM com-
plex mediates pro-inflammatory NF-kB activation in response toeports 17, 221–232, September 27, 2016 ª 2016 The Authors. 221
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
at least three G-protein-coupled receptor (GPCR) agonists,
Angiotensin II, CXCL8/interleukin-8 (IL-8), and thrombin (Delekta
et al., 2010; Martin et al., 2009; McAllister-Lucas et al., 2007,
2010). This in turn contributes to NF-kB-dependent induction
of adhesion molecules, facilitating the homing of immune cells
to sites of tissue inflammation (Delekta et al., 2010), yet a fully
effective inflammatory response also requires induced endothe-
lial permeability to allow these cells to transmigrate from the
vessel lumen into the subendothelial space. Here, we show
that CBM activation in endothelial cells has an additional, unan-
ticipated consequence in that the resulting MALT1 dependent
cleavage of CYLD triggers disruption of the endothelial barrier
and causes collapse of microvascular structures. These findings
thereby provide direct demonstration of MALT1 proteolytic ac-
tivity occurring in cells outside the immune system and in
response to a GPCR agonist instead of an antigenic challenge.
Further, the findings emphasize that MALT1 proteolytic activity
can impact cell physiology in an NF-kB-independent manner;
MALT1-dependent CYLD cleavage in this setting appears to
interfere with the role of CYLD in preserving microtubule integ-
rity, which is critical for maintenance of barrier function and is
distinct from the effects of CYLD on NF-kB signaling. Taken
together, the findings described here suggest that pharmaceu-
tical targeting of MALT1 protease activity may have broader
implications than previously expected. Specifically, MALT1 inhi-
bition may have applications that go beyond manipulation of im-
mune cell function and could have utility in modulating acute
vascular reactivity.RESULTS
Thrombin Induces Endothelial Permeability in a MALT1-
Protease-Dependent but NF-kB-Independent Manner
Previous studies have suggested that while MALT1 protease ac-
tivity has a major role in fine-tuning the level of NF-kB activation
achieved after lymphocytes are stimulated with antigen, there
may be other roles for the protease. For example, MALT1-
dependent cleavage of Bcl10 in lymphocytes has been linked
to alterations in integrin function (Rebeaud et al., 2008). To
further address this question, we asked if MALT1 and its proteo-
lytic activity impact any of the varied NF-kB-independent effects
of thrombin on endothelial cell biology. We had already shown
that thrombin stimulation of protease activated receptor-1
(PAR1), the principal thrombin receptor on endothelial cells, in-
duces NF-kB activation through the CBM pathway in a manner
very much analogous to the mechanism by which antigen recep-
tors induce NF-kB in lymphocytes (Delekta et al., 2010). How-
ever, PAR1 activation directs multiple other phenotypic alter-
ations in these cells. Notably, PAR1 activation produces a
rapid and reversible increase in paracellular endothelial perme-
ability (Hirano, 2007; Vandenbroucke et al., 2008). This effect is
thought to account for the ability of thrombin to inducemicrovas-
cular leakage and edema, as well as facilitate the transendothe-
lial migration of inflammatory cells at sites of vascular inflamma-
tion. Thus, we wondered if the CBM complex might also
participate in this aspect of the thrombin response, despite the
fact that rapid and transient permeability responses are not222 Cell Reports 17, 221–232, September 27, 2016thought to depend on NF-kB activation (Ka´sa et al., 2015; Mehta
and Malik, 2006; Sukriti et al., 2014).
This notion was motivated by the work of several laboratories
which showed that, in endothelial and other cell types, CYLD has
a critical role in binding to and stabilizing microtubules (Gao
et al., 2008, 2010; Li et al., 2014; Trompouki et al., 2009; Wick-
stro¨m et al., 2010; Yang et al., 2014; Yang and Zhou, 2016).
Upon CYLD depletion, microtubules are disassembled, an
event that can release microtubule-bound factors including at
least two Rho guanine nucleotide-exchange factors (GEFs),
Trio and RhoGEF-H1, as well as LIM kinase-1 (LIMK1); once
released, these factors are able to initiate a cascade of signaling
events that results in actin fiber reorganization and the conver-
sion of cortical actin into actin stress fibers (Birukova et al.,
2006; Gao et al., 2010; Gorovoy et al., 2005; Krendel et al.,
2002; Mikelis et al., 2015). This, coupled with disruption of
both adherens and tight junctions, leads to retraction of endo-
thelial cells from one another and paracellular permeability.
Given that CYLD had been described as a MALT1 cleavage
target in lymphocytes (Staal et al., 2011), we wondered whether
thrombin-induced, MALT1-dependent cleavage of CYLD would
occur in endothelial cells and have an effect similar to the genetic
deletion of CYLD. If so, rapid and dynamic CYLD cleavage would
represent a novel physiologic mechanism governing induced
endothelial permeability.
To test this notion, we first evaluated two distinct endothelial
cell lines, the human EA.hy926 line and the mouse SVEC
line, for PAR1-dependent alterations in permeability. This was
accomplished using electrical cell-substrate impedance sensing
(ECIS), a technique whereby changes in electrical resistance are
measured in real time, across confluent monolayers of endothe-
lial cells grown on gold-plated electrodes (Stolwijk et al., 2015)
(Figure 1A). We found that both cell lines express PAR1 and
respond rapidly to thrombin, with a drop in electrical resistance
reflecting an increase in paracellular permeability (Figures
S1A–S1C). Cells respond similarly when treated with thrombin
receptor activator peptide-6 (TRAP-6), a six-amino-acid peptide
that acts as a selective ligand for PAR1 and mimics thrombin
activation of this receptor (Coughlin, 2000) (Figure S1D). We
focused most subsequent evaluations on SVECs, since these
cells are derived from microvascular endothelium, the subpopu-
lation of endothelium most susceptible to physiologic, agonist-
induced alterations in permeability (Mehta and Malik, 2006).
Using siRNA transfection, we then knocked down MALT1 in
SVECs and found that this significantly impaired the ability of
TRAP-6 to induce an acute permeability response (Figures 1B
and 1C). In parallel, we pre-treated SVECs with z-VRPR-fmk,
a cell-permeable inhibitor of the MALT1 protease (Rebeaud
et al., 2008). Upon subsequent addition of TRAP-6, cells showed
a similarly blunted response in the permeability assay, suggest-
ing that MALT1 protease inhibition is as effective as MALT1
knockdown with regard to blocking PAR1-responsive endothe-
lial permeability (Figures 1D and 1E). Importantly, inhibiting ca-
nonical NF-kB activation with IKK-VI, a potent inhibitor of the
IKK complex, had no effect (Figures 1F and 1G). This is consis-
tent with the fact that the permeability response occurs very
rapidly, within10 min, a time frame during which PAR1-depen-
dent NF-kB activation is still at its early stages and before
Figure 1. The Thrombin Receptor, PAR1, Induces Acute Endothelial Permeability and Tube Disruption in a MALT1-Protease-Dependent but
NF-kB-Independent Manner
(A) A schematic of the ECIS system is shown. Paracellular permeability is indirectly proportional to the electrical resistance measured across the endothelial
monolayer
(B and C) MALT1 knockdown abrogates TRAP-6-induced acute endothelial permeability. SVECs were transfected with either control or MALT1-specific siRNAs
prior to measuring the permeability response to TRAP-6. (B) Representative tracings, (C) percent maximal decrease in resistance (mean ± SEM, n = 3; *p < 0.05).
(D and E) MALT1 protease inhibition abrogates TRAP-6-induced acute endothelial permeability. Untransfected SVECs were similarly plated in ECIS chambers
and subjected to treatment with TRAP-6, with or without a 4 hr pretreatment with z-VRPR-fmk (50 mM). (D) Shown are representative tracings and (E) percent
maximal decrease in resistance (mean ± SEM, n = 6; *p < 0.05).
(F and G) TRAP-6-induced acute endothelial permeability is not dependent on NF-kB activation. Untransfected SVECs were similarly plated in ECIS chambers
and subjected to treatment with TRAP-6, with or without a 0.5 hr pretreatment with IKK-VI (10 mM). (F) Shown are a representative set of tracings and (G) percent
maximal decrease in resistance (mean ± SEM, n = 4).
(H–K) MALT1 knockdown prevents TRAP-6-induced endothelial tube disruption. SVECs and EA.hy926 cells were transfected with control or MALT1-specific
siRNAs, plated on GFR Matrigel, and allowed to form capillary tube structures. TRAP-6 was added for four or more additional hours, at which time tubes were
fixed with formalin, photographed, and quantified. Representative phase contrast images are shown for SVECs (H) and EA.hy926 (I) cells. Tube quantification is
shown for multiple replicate experiments with SVECs (J) and EA.hy926 (K) cells (mean tube number/43 field ± SEM, n = 3; *p < 0.05). Insets: western analyses for
MALT1 knockdown efficiency.
(L–O) MALT1 protease inhibition, but not IKKb inhibition, prevents TRAP-6-induced endothelial tube disruption. Untransfected SVECs and EA.hy926 cells
were plated on GFR Matrigel and pretreated with either z-VRPR-fmk or IKK-VI prior to addition of TRAP-6. Representative phase contrast images are shown for
SVECs (L) and EA.hy926 (M) cells. Tube quantification is shown for multiple replicate experiments with SVECs (N) and EA.hy926 (O) cells (mean tube number/43
field ± SEM, n = 3; *p < 0.05).
See also Figures S1–S3.
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alterations in NF-kB target gene expression occur. As a control,
we found that IKK-VI treatment completely blocked PAR1-
dependent NF-kB activation in these cells, as evidenced by
the lack of pIkB induction following TRAP-6 treatment (Fig-
ure S1E). In contrast, z-VRPR-fmk did not prevent canonical
signaling to IkB (Figure S1E), consistent with what has been
shown in lymphocytes following antigen receptor activation
(Hailfinger et al., 2011). Taken together, these results indicate
that the acute permeability response induced by PAR1 activation
depends significantly on MALT1 and its proteolytic activity, but
not on NF-kB activation.
To test for a potentially broader role of MALT1 in regulating
endothelial permeability, we treated cells with two additional ag-
onists, histamine and lysophosphatidic acid (LPA). Both induced
rapid permeability responses, as evidenced by reductions in
electrical resistance in the ECIS assay, mimicking the actions
of thrombin (Figures S2A–S2D). Importantly, z-VRPR-fmk was
similarly effective at blocking the permeability response to either
agonist (Figures S2A–S2D). As a control, the permeability res-
ponse induced by nocodazole, a direct microtubule disruptor,
could not be prevented by z-VRPR-fmk, indicating that only
permeability responses that proceed through signaling path-
ways linked to the CBM complex are likely to be impacted by
MALT1 inhibition (Figures S2E and S2F). Indeed, like thrombin,
both histamine and LPA act through Gaq/11/Ga12/13-linked
GPCRs, which, at least in the case of LPA receptors, have
been shown to engage the CBM complex in other cellular con-
texts (Klemm et al., 2007; Wang et al., 2007). Thus, multiple
GPCRs likely initiate permeability signals that converge on
MALT1 in endothelial cells, so that MALT1 protease activation
could act as a central switch controlling the response to a range
of vasoactive substances.
MALT1 Protease Activation Disrupts Endothelial
Capillary Tubes in an NF-kB-Independent Manner
When plated in a 3D Matrigel matrix, endothelial cells spontane-
ously organize into tube-like structures, recapitulating capillary
networks (Sigurbjo¨rnsdo´ttir et al., 2014). The integrity of these
structures depends, in part, upon maintenance of continuous
contact between the endothelial cells, so that the same stimuli
that cause endothelial retraction and paracellular permeability
can also induce tube collapse (Bayless and Davis, 2004). Con-
sistent with this notion, we found that tubes formed from both
SVEC and EA.hy926 cells are disrupted by treatment with
either thrombin or TRAP-6 (Figures S3A–S3D). Importantly,
tube disruption was dramatically mitigated when cells were first
depleted of MALT1 through transfection with MALT1 small inter-
fering RNA (siRNA) (Figures 1H–1K). Similar to the permeability
response, we found that treatment with z-VRPR-fmk was as
effective as MALT1 knockdown at preventing PAR1-induced
tube disruption, while IKK-VI was unable to protect against the
disruption (Figures 1L–1O). Together, the above studies demon-
strate that PAR1 activation induces tube collapse through a
mechanism that relies on MALT1 and its protease activity, but
not on NF-kB activation. These findings parallel those from the
permeability studies, underscoring how downstream signaling
events diverge at the level of MALT1 in endothelial cells, with
protease activity governing multiple related aspects of acute224 Cell Reports 17, 221–232, September 27, 2016endothelial structural integrity through a mechanism that does
not involve the canonical NF-kB pathway.
Thrombin Receptor Activation Induces MALT1-
Dependent CYLD Cleavage in Endothelial Cells
CYLD is known to bind microtubules through two tandem cyto-
skeleton-associated protein glycine-conserved (CAP-Gly) do-
mains (Gao et al., 2008; Wickstro¨m et al., 2010) located in the
N terminus of the protein (Figure 2A). However, the CAP-Gly do-
mains alone are unable to efficiently mediate microtubule stabi-
lization (Trompouki et al., 2009). The C terminus of CYLD, which
contains a deubiquitination domain (DUB), is required for this
functionality. Although not fully understood, the C terminus ap-
pears to direct a complex array of binding and/or deubiquitina-
tion activities to inhibit microtubule disruptors, including dishev-
eled (dvl) and end-binding protein-1 (EB1) (Li et al., 2014; Yang
et al., 2014; Yang and Zhou, 2016). Regardless of the precise
mechanism, it appears that the N- and C-terminal domains func-
tion optimally only when together, with the N-terminal CAP-Gly
domains mediating the recruitment of CYLD to microtubules
and the C-terminal domain mediating necessary enzymatic or
other activities to fully stabilize microtubules.
Interestingly, the MALT1-specific cleavage site, as determined
through studies of activated T lymphocytes, is located just C-ter-
minal to the CAP-Gly domains, following position R324 (Staal
et al., 2011) (Figure 2A). As such,we reasoned thatMALT1-depen-
dent CYLD cleavage would separate the microtubule binding and
stabilization domains present withinCYLD, potentially rendering it
incapableofmaintainingmicrotubule integrity.To test this idea,we
first looked for evidence of PAR1-dependent CYLD cleavage in
SVEC and EA.hy926 cells, and we found that ten or moreminutes
of TRAP-6 treatment resulted in the generation of both the 70-kDa
and 40-kDa CYLD fragments that would be predicted to result
from cleavage at R324 (Figures 2B, 2C, S4A, and S4B). Treatment
with the natural PAR1 agonist thrombin had a similar effect (Fig-
ure 2D). Importantly, we found that generation of the CYLD cleav-
age fragments is mediated by MALT1 proteolytic activity, since it
could be inhibited by pretreatment with theMALT1-specific inhib-
itor z-VRPR-fmk, but not by the IKKb inhibitor IKK-VI (Figures 2E,
S4C, and S4D). To ensure that PAR1-dependent CYLD cleavage
is not a phenomenon restricted to immortalized endothelial cell
lines, we confirmed that CYLD cleavage also occurs in primary
human aortic endothelial cells (Figure S4E).
MALT1-Dependent CYLD Cleavage Drives Microtubule
Disruption and Associated ROCK Activation
Next, we tested whether blocking PAR1-induced MALT1 prote-
ase activity would correlate with a blockade in microtubule
disruption. Since stable microtubules are characterized by high
acetylated a-tubulin content, disruption of microtubules can be
assessed by measuring a drop in cellular acetylated a-tubulin
levels (Westermann and Weber, 2003). Indeed, TRAP-6-treated
SVECs showed a dramatic reduction in acetylated a-tubulin con-
tent, but importantly, this reduction was completely prevented
by pretreatment with the MALT1 protease inhibitor z-VRPR-
fmk (Figure 3A).
We then asked whether the specific cleavage of CYLD, as
opposed to cleavage of another unknown substrate of MALT1,
Figure 2. Thrombin Receptor Activation In-
duces MALT1-Dependent CYLD Cleavage
in Endothelial Cells
(A) Schematic of CYLD domain structure and
location of the MALT1 cleavage site.
(B and C) TRAP-6 induces CYLD cleavage in
endothelial cells. SVECs and EA.hy926 cells,
respectively, were treated with TRAP-6 (50 mM) for
the indicated times and analyzed for CYLD
cleavage. Separate antibodies were used to
detect the 40-kDa N-terminal and 70-kDa C-ter-
minal cleaved (Clv) fragments.
(D) Thrombin induces CYLD cleavage in endo-
thelial cells. SVECs were treated with either
thrombin (10 U/mL) or TRAP-6 (100 mM) and
analyzed by western blotting to compare CYLD
cleavage efficiency.
(E) MALT1 protease inhibition, but not IKKb inhi-
bition, prevents TRAP-6-induced CYLD cleavage
in endothelial cells. SVECs were pretreated with
either z-VRPR-fmk (50 mM; 4 hr) or IKK-VI (10 mM;
30 min). Cells were then treated with or without
TRAP-6 for an additional 30 min before assaying
for generation of the 70-kDa CYLD cleavage
fragment.
See also Figure S4.is linked to a-tubulin deacetylation. To this end, we generated
SVECs that stably express either wild-type CYLD or a non-cleav-
able mutant of CYLD, which contains a single amino acid substi-
tution converting the critical P1 arginine at the cleavage site to
alanine (R324A) (Staal et al., 2011) (Figure S5A). Cells expressing
wild-type CYLD, or those with empty vector only, responded to
thrombin with the expected drop in acetylated a-tubulin levels,
while those expressing non-cleavable R324A CYLD maintained
their acetylated a-tubulin levels in the face of thrombin treatment
(Figure 3B).
Given that acetylated a-tubulin levels are an indirect measure
of microtubule stability, we sought to directly visualize and quan-
titate microtubule dynamics in cells that express either exoge-
nous wild-type CYLD or the non-cleavable R324A CYLDmutant.
Thus, we generated derivative lines that also express GFP-
tagged EB1, which associates with the growing microtubule
plus ends and can be used as a dynamic marker of microtubule
polymerization and disruption via time-lapse confocal imaging
(Akhmanova and Steinmetz, 2015; Applegate et al., 2011; Matov
et al., 2010). Cells were imaged over a 2-min period immediately
before the addition of thrombin, and then again either immedi-
ately after addition (Figures 3C–3E), or following a 5 min delay
(Figures S5B and S5C). PlusTipTracker software was used toCell Repfollow EB1microtubule comets and cate-
gorize individual microtubules into fast or
slow growth categories, reflecting the
combined effects of microtubule catas-
trophe, pausing, and polymerization (Ap-
plegate et al., 2011). Consistent with pre-
vious work (Geyer et al., 2015), in the
2 min following thrombin stimulation,
control SVECs responded with a signifi-
cant reduction in overall microtubulegrowth rate, as did cells expressing wild-type CYLD (Figures
3C–3E). In contrast, cells expressing non-cleavable R324A
CYLD showed no measurable changes in microtubule dynamics
(Figures 3C–3E). At a point 5 min following thrombin stimulation,
cells expressing the R324A CYLD mutant began to show a
reduction in microtubule growth, but the overall growth rate re-
mained elevated as compared to the growth rate in control cells
at this time point (Figures S5B and S5C).
Because microtubule disruption has been linked to release of
at least two Rho GEFs, Trio and RhoGEF-H1 (Birukova et al.,
2006; Krendel et al., 2002; Mikelis et al., 2015; van Haren et al.,
2014), which subsequently activate ROCK, we sought to test
whether the non-cleavable R324A CYLD mutant can also sup-
press ROCK kinase activity following thrombin treatment.
Remarkably, while control cells and those expressing wild-type
CYLD responded to thrombin with rapid phosphorylation of the
major ROCK substrate myosin light chain (MLC), cells express-
ing R324A CYLD showed no detectable MLC phosphorylation
(Figure 3F). Phosphorylation of another ROCK substrate, the reg-
ulatory subunit of MLC phosphatase (MYPT1), on S507 and T696
was partially blunted in cells expressing R324A CYLD. However,
MYPT1 phosphorylation is known to be catalyzed not only by
ROCK but also by several other kinases (Mikelis et al., 2015).orts 17, 221–232, September 27, 2016 225
Figure 3. MALT1-Dependent CYLD Cleavage Is a Mediator of Microtubule Disruption and Downstream ROCK Activation
(A) MALT1 protease inhibition prevents TRAP-6 induced microtubule disruption. SVECs were treated with TRAP-6 for the indicated times, with or without a 4 hr
pretreatment with z-VRPR-fmk, and assayed for a decrease in cellular acetylated a-tubulin content, reflecting microtubule disruption.
(B) Non-cleavable R324ACYLD acts as a dominant negative to block thrombin induced a-tubulin deacetylation. SVECs stably expressing empty vector, wild-type
CYLD, or R324A CYLD were compared at varying times after thrombin addition. Representative western blots are shown at top, with dashed lines separating
distinct blot exposures. Quantification of the acetylated:total a-tubulin ratio from multiple experiments is shown at bottom (mean ± SEM, n = 3; **p < 0.01, ***p <
0.001).
(legend continued on next page)
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Figure 4. MALT1-Dependent CYLD Cleav-
age Is Mechanistically Linked to the Perme-
ability Response and Disruption of Endo-
thelial Tubes
(A and B) Non-cleavable R324A CYLD acts as a
dominant negative to abrogate TRAP-6-induced
endothelial permeability. SVECs expressing either
exogenous wild-type CYLD or the R324A mutant
were evaluated by ECIS for their permeability
response to TRAP-6. Shown are representative
tracings (A) and percent maximal decrease in
resistance (B) (mean ± SEM, n = 4–5; ***p < 0.001).
(C and D) Non-cleavable R324A CYLD acts as a
dominant negative to abrogate TRAP-6-induced
endothelial tube disruption. Transfected SVECs
were evaluated in the tube formation assay to test
their sensitivity to TRAP-6 mediated tube disrup-
tion. Images (C) and quantification (D) are shown
for one representative experiment (from n = 4)
performed in biological quadruplicate (mean tube
number/43 field ± SEM; ***p < 0.001).
See also Figure S6.Taken together, these results suggest that MALT1-dependent
CYLD cleavage drives microtubule disruption and subsequent
ROCK activation. ROCK, in turn, directly phosphorylates MLC
to promote actin-myosin stress fiber formation, while it also con-
tributes to the phosphorylation and inhibition of MLC phospha-
tase, thereby preserving levels of p-MLC.
CYLD Cleavage Is Mechanistically Linked to Endothelial
Barrier Disruption
Next, we asked whether the observed PAR1-responsive CYLD
cleavage is mechanistically linked to alterations in endothelial
cell barrier integrity. Control cells and those expressing exoge-
nous wild-type CYLD responded to TRAP-6 with the expected
acute permeability, but strikingly, cells expressing the R324A
CYLD mutant showed a blunted permeability response (Figures
4A and 4B). We then used the same approach to ask if PAR1-
responsive CYLD cleavage is mechanistically linked to an overall(C–E) Non-cleavable R324A CYLD blocks thrombin induced microtubule disruption. The indicated SVEC li
subjected to time-lapse confocal imaging to visualize and quantitate microtubule dynamics following thrombin
microtubule growth tracks for the 2min before and immediately after thrombin addition and colored based on
microtubule tracks for multiple cells under the conditions shown in (C). (E) Box and whisker plots of mic
acquisition (n = 530–1,042 tracks).
(F) Non-cleavable R324A CYLD abrogates thrombin induced MLC phosphorylation. The indicated cells wer
ROCK substrate sites T18 and S19. Phosphorylation of MYPT1 was also assessed at S507 and T696. As a c
IKK-dependent, phosphorylation of IkB, which as expected, was unaltered by the expression of either wild-
See also Figure S5.
Cell Repdestabilization of endothelial contacts
and the loss of structural integrity that un-
derlies tube collapse. As with the perme-
ability assay, cells expressing wild-type
CYLD responded to TRAP-6 with the
expected tube dissolution, but those
expressing non-cleavable CYLD main-
tained nearly complete tube integrity in
the face of TRAP-6 treatment (Figures4C and 4D). Thus, this CYLDmutant, resistant to MALT1-depen-
dent cleavage (Staal et al., 2011), acts in a dominant-negative
fashion, suggesting that CYLD cleavage is required for efficient
PAR1-induced endothelial permeability and tube disruption.
The results support the overall hypothesis that cleavage-
dependent separation of theCYLDN-terminal microtubule-bind-
ing and C-terminal microtubule-stabilization domains renders
the protein unable to perform its functions with regard to main-
taining microtubules. Viewed in this light, cleavage of CYLD
would mechanistically represent a loss-of-function response.
However, we also considered the possibility that CYLD cleavage
might represent a gain-of-function response if either the newly
formed 40-kDa fragment or 70-kDa fragment gains new func-
tionality, allowing it to actively promote microtubule disas-
sembly. To rule out this possibility, we transfected cells with
expression vectors encoding either wild-type CYLD or these
CYLD fragments in order to mimic their production in the settingnes were engineered to co-express GFP-EB1 and
treatment. (C) Representative cell images showing
growth parameter subcategories. (D) Distribution of
rotubule growth rates during the period of image
e assayed for dual phosphorylation of MLC at the
ontrol, cells were evaluated for thrombin-induced,
type or mutant CYLD.
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Figure 5. Endothelial Cells fromMALT1PD/PD Mice Are Resistant to Thrombin-Receptor-Induced CYLD Cleavage, Microtubule Disassembly,
and Acute Permeability Alterations
(A and B) MALT1 protease-defective endothelial cells do not demonstrate CYLD cleavage in response to PAR1 stimulation. Pulmonary endothelial cells were
isolated from wild-type mice (MALT1WT/WT) and mice homozygous for a single codon mutation in the MALT1 locus (MALT1PD/PD), which encodes for a single
amino acid substitution at the catalytic cysteine of the MALT1 protease, rendering it catalytically inactive (protease dead [PD]). Cells were treated with TRAP-6
(50 mM) for the indicated times and assayed for both NF-kB activation and CYLD cleavage. (A) Blots from a representative experiment are shown. (B) The ratio of
cleaved (40 kDa) to full-length (FL) CYLD was determined by densitometry and averaged for multiple experiments (error bars represent SEM, n = 5; *p < 0.05).
(C and D) MALT1 protease-defective endothelial cells fail to show biochemical evidence of microtubule disruption in response to PAR1 stimulation. Primary
endothelial cells from wild-type and PD mice were isolated, treated with TRAP-6, and assayed for loss of acetylated a-tubulin, reflecting microtubule destabi-
lization. (C) Blots from a representative experiment are shown. (D) The ratio of acetylated to total a-tubulin was determined by densitometry and averaged for
multiple experiments (error bars represent SEM, n = 3; **p < 0.01).
(E and F) MALT1 protease-defective endothelial cells show a blunted permeability response following PAR1 stimulation. Primary endothelial cells from wild-type
and PDmice were evaluated by ECIS for TRAP-6-induced permeability responses. (E) A representative set of tracings is shown. (F) Percent maximal decrease in
resistance under the four conditions is shown (mean ± SEM, n = 7; **p < 0.01).
(G and H) MALT1PD/PD mice are resistant to PAR1-responsive pulmonary vascular leakage. (G) Representative lungs excised from mice following combined
Evans blue dye and TRAP-6 infusion, demonstrating enhanced blue dye tissue extravasation in lungs from MALT1WT/WT mice as compared to those from
MALT1PD/PD mice. (H) Quantification of the change in blue dye extravasation following TRAP-6 administration, relative to PBS administration, in MALT1WT/WT and
MALT1PD/PD mice (mean ± SEM, n = 8; ***p = 0.001)of PAR1 stimulation (Figure S6A). In each case, cells established
and maintained tube networks as efficiently as cells transfected
with control glutathione S-transferase (GST)-expressing vector
(Figures S6B and S6C). Thus, it is unlikely that the generation
of CYLD fragments unmasks new functionality that actively
contributes to loss of endothelial structural integrity and tube
disruption.
MALT1PD/PD Mice Exhibit Resistance to Thrombin-
Receptor-Induced CYLD Cleavage and Endothelial Cell
Permeability
Finally, we took a genetic approach to testing the role of
MALT1 proteolytic activity in promoting endothelial destabili-
zation by generating knockin mice homozygous for a prote-
ase-dead MALT1 allele (MALT1PD/PD) (Yu et al., 2015). These
mice were engineered to harbor a single codon missense mu-
tation (TGT > GCC) in exon 12, resulting in a single amino acid
substitution at the critical catalytic cysteine (C472A), which is228 Cell Reports 17, 221–232, September 27, 2016known to cripple the protein’s enzymatic activity (Coornaert
et al., 2008; Rebeaud et al., 2008). Primary pulmonary endo-
thelial cells from 4-week-old mice were isolated and cultured
in vitro and compared with cells isolated from wild-type
mice. As expected, MALT1PD/PD endothelial cells maintained
responsiveness to TRAP-6 with respect to canonical NF-kB
activation, demonstrating that the scaffolding role of MALT1
remains intact in the face of the C472A mutation, and activa-
tion of the IKK complex still occurs normally (Figure 5A). In
contrast, TRAP-6-induced CYLD cleavage was abolished (Fig-
ures 5A and 5B).
Furthermore, we found that the loss of protease activity was
linked to a loss in PAR1-responsive microtubule destabilization;
while wild-type cells responded to TRAP-6 with a time-depen-
dent decrease in acetylated a-tubulin levels, reflecting microtu-
bule disassembly, MALT1PD/PD cells showed no significant
decrease (Figures 5C and 5D). In fact, there was a slight in-
crease in acetylated a-tubulin content. Most remarkable, when
Figure 6. Model of a MALT1-Dependent
Signaling Cascade Driving Endothelial
Permeability
In this model, MALT1 protease activity, induced by
the thrombin receptor and possibly other related
GPCRs, including those for histamine and LPA,
cleaves microtubule-associated CYLD, leading to
microtubule instability. This serves to free at least
two Rho GEFs, which may then redistribute to the
plasma membrane and associate with Gaq or
Ga12/13 to activate RhoA. ROCK is subsequently
activated and carries out a series of phosphory-
lations to promote formation of actin-myosin
stress fibers. These stress fibers exert tension on
vascular-endothelial (VE) cadherins, organized
into focal adherens junctions (FAJs), to effectively
disrupt the endothelial barrier. While the data
presented here suggest that the above pathway
plays amajor role in the permeability response, it is
important to note that additional, redundant
pathways clearly exist that are similarly important.
For example, microtubule stability depends not
only on CYLD integrity but also on a number of
other microtubule binding and regulatory proteins,
including Tau, EB1, CLIP-170, MAP4, stathmin,
VHL, andmany others (Bhat and Setaluri, 2007). At
least some of these are known to be inhibited by thrombin through mechanisms that are unlikely to involve MALT1. Parallel pathways for MLC phosphorylation
that do not necessarily require microtubule disruption also exist; for example, the Ca2+/calmodulin dependent activation of myosin light chain kinase (MLCK) may
independently promote actin-myosin stress fibers (Somlyo and Somlyo, 2003). Finally, induced permeability requires modification and disassembly of both tight
and adherens junctions, all of which are tightly regulated by a host of regulatory factors (Dudek and Garcia, 2001). Indeed, given the array of redundant and
parallel pathways, it is remarkable that endothelial cells from mice harboring only a single codon substitution within the genome, affecting a single amino acid in
the catalytic domain of MALT1, display such significant alterations in the endothelial permeability response.evaluated by ECIS, we found that primary endothelial cells from
MALT1PD/PD mice were also significantly protected from the
TRAP-6-induced acute permeability response (Figures 5E and
5F).
To test acute endothelial permeability responses in vivo, we
utilized a pulmonary vascular leak model. Specifically, we
perfused mice through the jugular vein with Evans blue dye
along with either TRAP-6 or PBS vehicle, as described previ-
ously (Kaneider et al., 2007; Patterson et al., 1992). Mice
were sacrificed, and transendothelial extravasation of albu-
min-bound Evans blue dye was quantified in excised lungs.
While lungs from wild-type mice showed visible and spectro-
photometrically quantifiable increases in Evans blue dye ex-
travasation (40% increase), lungs from MALT1PD/PD mice
showed a slight decrease in extravasation relative to PBS-
treated controls (30% decrease) (Figures 5G and 5H). Thus,
MALT1PD/PD mice showed protection from thrombin-receptor-
induced acute pulmonary edema. Taken together, the in vitro
and in vivo results indicate that altering the genome by intro-
ducing only a single codon mutation in the MALT1 gene to
disable its protease domain is sufficient to effect a substantial
change in endothelial cell reactivity.
DISCUSSION
MALT1 has a well-known role as the effector protein of the CBM
complex in immune cells and mediates critical NF-kB-driven
adaptive immune responses (Thome, 2004). The direct NF-kB in-
duction mediated by MALT1 is thought to occur primarilythrough its scaffolding activity, whereby it recruits IKK activating
enzymes to bring them into proximity with NF-kB essential
modulator (NEMO) and the other components of the IKK com-
plex (Afonina et al., 2015). The proteolytic activity of MALT1 in
immune cells has been largely viewed as a mechanism for purg-
ing negative regulators of downstream NF-kB signaling, thereby
maintaining optimal, sustained NF-kB-dependent transcriptional
activity.
Beyond its role in immune cells, MALT1 promotes NF-kB acti-
vation in endothelial cells in response to several GPCR ligands
(Delekta et al., 2010; Martin et al., 2009; McAllister-Lucas
et al., 2010). This results in expression of cell-surface adhesion
molecules such as intercellular adhesion molecule (ICAM) and
vascular cell adhesion molecule (VCAM), which work in concert
to recruit activated immune cells to sites of tissue inflammation.
The studies described here now demonstrate MALT1 proteolytic
activity occurring in cells outside the immune system, namely in
endothelial cells. Furthermore, this MALT1 proteolytic activity
has a surprising biologic effect unrelated to NF-kB signaling;
specifically, MALT1-dependent CYLD cleavage acutely alters
endothelial structural integrity, thereby impacting vascular
permeability (Figure 6). The data presented here are consistent
with a model whereby CYLD cleavage initiates microtubule
disruption and release of Rho GEFs. As suggested by Mikelis
et al. (2015), the redistribution of these Rho GEFs may allow
them to interact directly with GPCR-proximal Gaq and sub-
sequently activate RhoA and ROCK to promote MLC phosphor-
ylation and the assembly of actin-myosin stress fibers (Figure 6).
Although our data focus mostly on the role of this pathwayCell Reports 17, 221–232, September 27, 2016 229
in thrombin receptor (PAR1)-mediated endothelial responses,
findings presented in Figure S2 suggest that the pathway may
also be relevant to histamine receptor (H1R)- and LPA re-
ceptor (LPAR)-mediated permeability responses. Thus, MALT1
appears to have a dual role in the vasculature, facilitating both
leukocyte recruitment via induction of NF-kB-responsive adhe-
sion molecules, and transmural leukocyte migration via an NF-
kB-independent effect on the permeability barrier. Together,
these concepts illustrate that MALT1 proteolytic activity has
consequences that are substantially more far-reaching than
previously appreciated, impacting cell biologic processes that
are unrelated to NF-kB signaling or downstream transcriptional
reprogramming.
These findings also suggest that pharmaceutical targeting of
the MALT1 protease may have impact on aspects of inflamma-
tion that relate not only to lymphocytes and other immune cells
but also to the cells of the microenvironment in which inflamma-
tion takes place. Specifically, MALT1 inhibitionmay abrogate the
transmigration of activated immune cells through the endothelial
barrier, dampening localized tissue inflammation. There are mul-
tiple settings in which this could have therapeutic benefit. For
example, widespread pulmonary endothelial permeability, with
concomitant pulmonary edema and airspace inflammation, is
a major pathologic feature of sepsis-related acute lung injury
(ALI) and associated acute respiratory distress syndrome
(ARDS) (Matthay et al., 2012). Vasoactive substances, including
thrombin, histamine, and LPA, mediate this dramatic endothelial
response, yet most current therapies are generally supportive in
nature, rather than based on amechanistic understanding of dis-
ease pathogenesis (Matthay et al., 2012). We propose that in the
acute setting, MALT1 protease inhibitors might have efficacy in
reducing this underlying pathogenic feature of ARDS by specif-
ically targeting a mechanism driving endothelial permeability.
In the chronic setting, MALT1 inhibitors might be effective in
reducing the intimal inflammation of atherosclerotic disease.
Since active inflammation in the intimal/sub-endothelial space
is a critical feature that distinguishes unstable atherosclerotic
plaque, susceptible to rupture, from stable plaque (Hansson
et al., 2015; Weber and Noels, 2011), one could speculate that
MALT1 inhibition might reduce transmigration of activated leu-
kocytes through the arterial endothelial barrier and into this
space, thereby reducing the risk of acute coronary events in
the setting of advanced atherosclerosis.
Recently, several pharmaceuticals have been identified that
act as selective MALT1 protease inhibitors (Fontan et al., 2012;
Nagel et al., 2012; Schlauderer et al., 2013; Xin et al., 2016).
Because some of these are well-known phenothiazines, a class
of pharmaceuticals that have been used for treatment of psychi-
atric disorders, the potential exists for their rapid redeployment
to these novel therapeutic arenas. Thus, themechanistic insights
described here lay the foundation for an exciting and unexpected
opportunity to explore a specific concept for drug repurposing,
with application to the field of vascular biology.EXPERIMENTAL PROCEDURES
An extended version can be found in the Supplemental Experimental
Procedures.230 Cell Reports 17, 221–232, September 27, 2016Mice
MALT1PD/PD mice were generated with the assistance of genOway and have
been recently described (Yu et al., 2015). See the Supplemental Experimental
Procedures for a detailed description.
Cell Lines and Reagents
EA.hy926 cells were a gift fromCora-Jean Edgell (University of North Carolina).
SVECs (SVEC4-10) were obtained from ATCC. Primary human coronary artery
endothelial cells (HcAECs) were purchased from Lonza, cultured in EGM-2MV,
and used for no more than five passages. See the Supplemental Experimental
Procedures for details on these and all other reagents.
Endothelial Cell Isolation
Mouse primary pulmonary endothelial cells were isolated using a two-step se-
lection procedure, based on sequential purification with anti-mouse CD31 and
anti-mouse CD102. See the Supplemental Experimental Procedures for details.
Tube Formation and Electric Cell-Substrate Impedance Sensing
Tube formation assays were performed on growth-factor-reduced (GFR)
Matrigel Matrix (BD Biosciences) and visualized using either phase contrast
microscopy or fluorescence microscopy after staining with ActinRed 555
ReadyProbes reagent (Life Technologies). Quantification was performed
with either Image-ProPlus optical imaging software (Media Cybernetics) or
Nikon Elements software. Endothelial cell permeability was measured using
an ECIS ZQ instrument (Applied Biophysics), with a 16-well array station
and 8-well chamber slides (8W10E+). See the Supplemental Experimental Pro-
cedures for details on both of these procedures.
Live-Cell Imaging of Microtubule Dynamics
Imaging was carried out using a Nikon A1plus confocal galvano scanner
mounted on a Nikon Eclipse Ti microscope. Images were acquired at 1- to
2-s intervals for 2 min, and microtubules were automatically tracked using
PlusTipTracker software. See the Supplemental Experimental Procedures
for a detailed description.
Assessment of Pulmonary Vascular Leakage
Mice were perfused with Evans blue dye, administered through the external ju-
gular vein, and treated with or without TRAP-6. Extravascular Evans blue dye
was quantified from perfused, excised lungs using formamide extraction and
spectrophotometric quantification at 620 and 740 nm. See the Supplemental
Experimental Procedures for a detailed description.
Statistical Analysis
When experiments involved only two conditions, differences in means were
evaluated for statistical significance using a one- or two-tailed, unpaired Stu-
dent’s t test, as appropriate. For datasets involving multiple treatments and a
control, data were analyzed using one-way ANOVA. In the latter case, signifi-
cant differences between treatments were assessed using Tukey’s test, while
Dunnett’s test was used to compare each individual treatment to controls.
Sidak’s correction was used to account for multiple testing. All statistical
analyses were performed using GraphPad Prism, version 6.0 (GraphPad
Software). Data are presented as means ± SEM or as percent of control,
and p values are shown in either the figures or the figure legends.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.08.080.
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